AKT1 and neoplasm: Previous studies have provided some evidence that increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.44 As expected, combined MK2206 and cisplatin significantly reduced tumor growth in the OS patient-derived xenograft (PDX) mouse model.